



Innovative Medicines Initiative

First achievements and new challenges ahead

Michel Goldman
Executive Director



Annual Stakeholder Forum, 14-15 June 2010



efpia



IMI Executive Office as a Neutral Third-Party




- To implement programmes and activities in the common interest of all stakeholders
- To monitor the combined use of public funds and industry investment
- To guarantee fair and reasonable conditions for optimal knowledge exploitation and dissemination



The Call Process



Overall Structure of Research Projects



“Applicants consortium”

IMI beneficiaries



“EFPIA consortium”

EFPIA *in kind* contribution
(no public funding)



Ongoing Projects (1st Call)



15 Projects
395 Teams
Total budget:
281 M€

<i>Acronym</i>	<i>EFPIA Coordinator</i>	<i>Budget (M€)</i>
SAFE-T	Novartis Pharma	35.9
PROTECT	European Medicines Agency	29.8
SUMMIT	Boehringer Ingelheim	28.4
PHARMA-COG	GSK	27.7
IMIDIA	Sanofi-Aventis	25.4
NEWMEDS	Lundbeck	24.0
U-BIOPRED	Novartis Pharma	20.6
EUROPAIN	AstraZeneca	18.2
PROactive	Chiesi Farmaceutici	16.7
MARCAR	Novartis Pharma	13.3
E-TOX	Novartis Pharma	12.9
EMTRAIN	AstraZeneca	7.7
EU2P	F. Hoffman-La Roche	7.2
Pharma Train	Eur. Federation of Courses	6.6
SafeSciMET	F. Hoffman-La Roche	6.3

SMEs in Ongoing Projects



24 Companies
13.9 M €

AEROCRINE	U-BioPred
ALZPROTECT	PharmaCOG
ARGUTUS MEDICAL	Safe-T
BIOCOMPUTING PLATFORMS	Summit
BIOSCIENCE CONSULTING	U-BioPred
CHEMOTARGETS	E-Tox
CHOICE PHARMA	Proactive
CXR BIOSCIENCES	Marcar
EDI GMBH	Safe_T
ENDOCELLS SARL	Imidia
EXONHIT THERAPEUTICS SA	PharmaCOG
FIRALIS S.A.S.	Safe-T

GABO:MI	Newmeds
INNOVATIVE CONCEPTS	PharmaCOG
INNOVATIVE HEALTH DIAGNOSTICS	PharmaCOG
INTE:LIGAND SOFTWARE	E-Tox
INTERFACE EUROPE	Safe_T
ISLENSK ERFDAGREINING	Newmeds
LEAD MOLECULAR DESIGN	E-Tox
MOLECULAR NETWORKS GMBH	E-Tox
NEUROSCIENCE TECHNOLOGIES	Europain
OUTCOME EUROPE	Protect
QUALISSIMA	PharmaCOG
SYNAIRGEN RESEARCH	U-BioPred

OPPORTUNITIES

- Networking - deal opportunities
- Access to multicentric studies on large cohorts
- International visibility
- Private fund opportunities

THREATS

- Transfer or sharing of the IP and know-how
- Diffusion of sensitive information
- Administrative burden



Regulators in Ongoing Projects



- European Medicines Agency (EMA)
- MHRA (UK)
- DKMA (DK)
- AEMPS (SP)
- SwissMedic (CH)
- AFSSAPS (FR)



Patients' Organizations in Ongoing Projects



- Int. Alliances of Patients' Organizations
- Alzheimer's Europe
- Eur. Genetic Alliances' Netw.
- Genetic Interest Group
- European AIDS Treatment Group

- European Lung Foundation
- Int. Primary Care Resp. Group
- British Lung Foundation
- Asthma UK
- Lega Italiano Anti-Fumo
- Dutch Asthma Foundation



Lessons from Ongoing Projects



- **IMI is more than an industry-academia PPP:**
successful involvement of regulatory agencies, patients' organizations and SMEs
- **First successes and enthusiasm** provide « **proof-of-concept** »
evidence for IMI-type PPPs
- **Boundaries of pre-competitive research and IP rules** sometimes difficult to define
- Need for dedicated tools for **data and knowledge management**



2nd Call for Proposals (1)



124 Expression of Interests

1118 Applicants

Topics

- Knowledge Management
- Cancer Biomarkers
- Rapid diagnosis for infections
- Inflammatory disorders



2nd Call for Proposals (2)



- Participation of **25 Member States** (All 27 MS except Malta and Latvia) ;
- Participation from **7 FP7 Associated Countries**: Albania, Bosnia, Israel, Norway, Serbia, Switzerland, Turkey;
- Participation from **7 FP7 Third Countries**: Canada, China, Korea, Russian Federation, Senegal, Ukraine, United States


38 patients' organizations
204 SMEs



Open Innovation in the Health Sector: Major Challenges Ahead



- Involvement of patients and laypersons
- Frontiers of pre-competitive research
- Indicators of performance
- Management of intellectual property





Innovative Medicines Initiative

THANK YOU !



Annual Stakeholder Forum, 14-15 June 2010



efpia*